Alpelisib is a selective inhibitor of the catalytic alpha subunit of PI3K (PIK3CA), and it is registered for the treatment of metastatic HR+/HER2-PIK3CA-mutated breast cancer in combination with endocrine therapy [77]. This evidence concerns the gene ERBB2 and breast cancer.